Statins could be of potential therapeutic effect in asthma due to their pleiotropic effects on inflammation process. This study aimed to examine the possible interaction of serum lipids, and evaluate the effect of rosuvastatin treatment on asthma. Seven groups of rats, namely control (C), asthmatic (A), hyperlipidemic (H), asthmatic-hyperlipidemic (AH), rosuvastatin (40 mg/kg)-treated asthmatic (AR), rosuvastatin-treated hyperlipidemic (HR), and rosuvastatin-treated hyperlipidemic-asthmatic (AHR) groups, were studied. Total and differential WBC counts, serum oxidative stress markers, and bronchoalveolar lavage fluid (BALF) levels of IL-6 and IL-10 were evaluated. In the A and AH groups, total and differential WBC counts, and IL-6 and IL-10 levels were higher than in the C group (p<0.05 to p<0.001). An increase in nitrite and malondialdehyde concentrations and a decrease in total thiol content and superoxide dismutase and catalase activities were observed in the A, H, and AH groups compared to the C group (p<0.05 to p<0.001). Beyond lipid lowering, rosuvastatin treatment reduced total and differential WBC counts in the A and AH groups (p<0.05 to p<0.001), IL-6 level in the AH group (p<0.05), and IL-10 level in all treated groups (p<0.05). Rosuvastatin reduced oxidative stress by decreasing nitrite and malondialdehyde concentrations, and increasing total thiol content in all treated groups as well as superoxide dismutase and catalase activities in the H and AH groups (p<0.05 to p<0.01). Rosuvastatin reduced airway inflammation and oxidation through regulating NOS and reducing pro-inflammatory cytokine and inflammatory cells, which indicate a novel insight into the pleiotropic effects of rosuvastatin in treatment of asthma.

他汀类药物由于其对炎症过程的多效性作用，可能对哮喘具有潜在的治疗作用。本研究旨在探讨血清脂质可能存在的相互作用，并评估瑞舒伐他汀治疗哮喘的效果。七组大鼠，分别为对照组（C）、哮喘组（A）、高脂血症组（H）、哮喘-高脂血症组（AH）、瑞舒伐他汀（40 mg/kg）治疗哮喘组（AR）、瑞舒伐他汀治疗高脂血症组（HR），和瑞舒伐他汀治疗的高脂血症哮喘（AHR）组进行了研究。评估了白细胞总数和差异计数、血清氧化应激标志物以及支气管肺泡灌洗液 (BALF) 中 IL-6 和 IL-10 的水平。在 A 组和 AH 组中，白细胞总数和分类计数以及 IL-6 和 IL-10 水平高于 C 组（p<0.05 至 p<0.001）。与 C 组相比，A、H 和 AH 组中亚硝酸盐和丙二醛浓度增加，总硫醇含量以及超氧化物歧化酶和过氧化氢酶活性降低（p<0.05 至 p<0.001）。除了降脂之外，瑞舒伐他汀治疗还降低了 A 组和 AH 组的总白细胞计数和差异白细胞计数（p<0.05 至 p<0.001）、AH 组的 IL-6 水平（p<0.05）以及所有治疗组的 IL-10 水平组（p<0.05）。瑞舒伐他汀通过降低亚硝酸盐和丙二醛浓度、增加所有治疗组的总硫醇含量以及 H 和 AH 组中的超氧化物歧化酶和过氧化氢酶活性来减少氧化应激（p<0.05 至 p<0.01）。瑞舒伐他汀通过调节 NOS 和减少促炎细胞因子和炎症细胞来减少气道炎症和氧化，这表明瑞舒伐他汀在哮喘治疗中的多效作用具有新的见解。